Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Margot S.F. Roeten, Johan van Meerloo, Zinia Kwidama, Gaye Jenkins, Suzanne N. van Dijk, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J.L. Kaspers, Sonja Zweegman, Gerrit Jansen, Jacqueline Cloos, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 9183–9184.

https://doi.org/10.1182/blood-2022-162412

Published: 2022

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Niels Franke, MD, Gertjan J.L. Kaspers, MD PhD, Yehuda G Assaraf, PhD, Johan Van Meerloo, MSc, Denise Niewerth, PhD, Terzah M. Horton, MD PhD, Wee Joo Chng, MD PhD, Chonglei Bi, B.S, Rene X. Menezes, PhD, Renée J. Musters, PhD, Pino J. Poddighe, PhD, Floortje Kessler, Serge Smeets, PhD, Bauke Ylstra, PhD, Sonja Zweegman, MD PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2015) 126 (23): 3712.

https://doi.org/10.1182/blood.V126.23.3712.3712

Published: 2015

Journal Articles

Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML

Anna Wojtuszkiewicz, MSc, Yehuda G Assaraf, PhD, Gerrit Jansen, PhD, Kazunori Koide, PhD, Robert K. Bressin, Upamanyu Basu, Edwin Sonneveld, PhD, Elisa Giovannetti, PhD, Gertjan Kaspers, MD PhD, Jacqueline Cloos, PhD

Blood (2014) 124 (21): 924.

https://doi.org/10.1182/blood.V124.21.924.924

Published: 2014

Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD

Blood (2013) 122 (21): 3841.

https://doi.org/10.1182/blood.V122.21.3841.3841

Published: 2013

Journal Articles

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Yehuda Assaraf, PhD, Johan van Meerloo, MSc, Christopher J Kirk, PhD, Sonja Zweegman, MD, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 1346.

https://doi.org/10.1182/blood.V120.21.1346.1346

Published: 2012

Journal Articles

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Jing Fang, Garrett Rhyasen, Lyndsey Bolanos, Christopher Rasch, Melinda Varney, Mark Wunderlich, Susumu Goyama, Gerrit Jansen, Jacqueline Cloos, Carmela Rigolino, Agostino Cortelezzi, James C. Mulloy, Esther N. Oliva, Maria Cuzzola, Daniel T. Starczynowski

Blood (2012) 120 (4): 858–867.

https://doi.org/10.1182/blood-2012-02-407999

Published: 2012

Includes: Supplemental data

Journal Articles

Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Johan van Meerloo, MSc, Yehuda Assaraf, Prof, Christopher J Kirk, Elena T Chan, Sonja Zweegman, MD, PhD, Gertjan J. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2011) 118 (21): 1513.

https://doi.org/10.1182/blood.V118.21.1513.1513

Published: 2011

Journal Articles

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

Niels E Franke, MD, MSc, Johan van Meerloo, B.ASc, Linda Slot, MSc, Xiaoming Li, PhD, Tabitha E Wood, PhD, Katarina Vojtekova, MSc, Sue Ellen Verbrugge, MSc, Gertjan Kaspers, MD, PhD, Robert A. Batey, PhD, Aaron D. Schimmer, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2009) 114 (22): 940.

https://doi.org/10.1182/blood.V114.22.940.940

Published: 2009

Journal Articles

Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia

Robert de Jonge, Wim J. E. Tissing, Jan Hendrik Hooijberg, Gerrit Jansen, Gertjan J. L. Kaspers, Jan Lindemans, Godefridus J. Peters, Rob Pieters

Blood (2009) 113 (10): 2284–2289.

https://doi.org/10.1182/blood-2008-07-165928

Published: 2009

Journal Articles

Acquired Resistance to Bortezomib in Human RPMI-8226 Multiple Myeloma Cells: Molecular Characterization, Cross-Resistance with Other Proteasome Inhibitors but Marked Sensitization to Glucocorticoids

Niels E Franke, MD, MSc, Gertjan L Kaspers, MD, PhD, Nynke van den Berg, Ina van Zantwijk, Katarina Vojtekova, MSc, Uzma Yaqub, BSc, Serge Smeets, MSc, Bauke Ylstra, PhD, Sonja Zweegman, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2008) 112 (11): 2640.

https://doi.org/10.1182/blood.V112.11.2640.2640

Published: 2008

Journal Articles

Acquisition of Mutations in the PSMB5 Gene during Chronic Exposure of Human Acute Lymphoblastic Leukemia CCRF-CEM Cells to the Proteasome Inhibitor Bortezomib

Niels E Franke, MD, MSc, Ruud Oerlemans, MSc, Ina van Zantwijk, Katarina Vojtekova, MSc, Gertjan L Kaspers, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2008) 112 (11): 2642.

https://doi.org/10.1182/blood.V112.11.2642.2642

Published: 2008

Journal Articles

Molecular basis of bortezomib resistance: proteasome subunit β5 ( PSMB5 ) gene mutation and overexpression of PSMB5 protein

Ruud Oerlemans, Niels E. Franke, Yehuda G. Assaraf, Jacqueline Cloos, Ina van Zantwijk, Celia R. Berkers, George L. Scheffer, Kabir Debipersad, Katharina Vojtekova, Clara Lemos, Joost W. van der Heijden, Bauke Ylstra, Godefridus J. Peters, Gertjan L. Kaspers, Ben A. C. Dijkmans, Rik J. Scheper, Gerrit Jansen

Blood (2008) 112 (6): 2489–2499.

https://doi.org/10.1182/blood-2007-08-104950

Published: 2008

Includes: Supplemental data

Journal Articles

A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration

Rieneke van de Ven, George L. Scheffer, Anneke W. Reurs, Jelle J. Lindenberg, Ruud Oerlemans, Gerrit Jansen, Jean-Pierre Gillet, Joel N. Glasgow, Alexander Pereboev, David T. Curiel, Rik J. Scheper, Tanja D. de Gruijl

Blood (2008) 112 (6): 2353–2359.

https://doi.org/10.1182/blood-2008-03-147850

Published: 2008

Journal Articles

A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function

Inbal Lasry, Bluma Berman, Rachel Straussberg, Yael Sofer, Hanna Bessler, Mohamad Sharkia, Fabian Glaser, Gerrit Jansen, Stavit Drori, Yehuda G. Assaraf

Blood (2008) 112 (5): 2055–2061.

https://doi.org/10.1182/blood-2008-04-150276

Published: 2008

Includes: Supplemental data

Journal Articles

Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.

Niels E. Franke, MD, Ruud Oerlemans, MSc, Sonja Zweegman, MD, PhD, Ina van Zantwijk, Gertjan J. Kaspers, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2007) 110 (11): 3469.

https://doi.org/10.1182/blood.V110.11.3469.3469

Published: 2007

Journal Articles

Ex Vivo Activity of Bortezomib and Dexamethasone Combinations Against Childhood Acute Leukemia Cells.

Niels E. Franke, MD, Ina van Zantwijk, Gertjan J. Kaspers, MD,PhD, Josefien Vink, MSc, Dirk Reinhardt, MD,PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2007) 110 (11): 4205.

https://doi.org/10.1182/blood.V110.11.4205.4205

Published: 2007

Journal Articles

Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss

Yotam Kaufman, Ilan Ifergan, Lilah Rothem, Gerrit Jansen, Yehuda G. Assaraf

Blood (2006) 107 (8): 3288–3294.

https://doi.org/10.1182/blood-2005-10-4048

Published: 2006

Journal Articles

Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy

Kambiz Fotoohi, Gerrit Jansen, Yehuda G. Assaraf, Lilah Rothem, Michal Stark, Ietje Kathmann, Jacek Gregorczyk, Godefridus J. Peters, Freidoun Albertioni

Blood (2004) 104 (13): 4194–4201.

https://doi.org/10.1182/blood-2004-04-1493

Published: 2004

Journal Articles

Disparate Mechanisms of Antifolate Resistance Provoked by Methotrexate and Its Metabolite 7-Hydroxymethotrexate in Leukemia Cells: Implications for Efficacy of Methotrexate Therapy.

Freidoun Albertioni, Gerrit Jansen, Kambiz Fotoohi, MD, Yehuda G. Assaraf, Lilah Rothem, PHD, Michal Stark, PHD, Letje Kathmann, PHD, Jacek Gregorczyk, PHD, Godefridus J. Peters

Blood (2004) 104 (11): 4369.

https://doi.org/10.1182/blood.V104.11.4369.4369

Published: 2004

NARROW

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells

Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia

Acquired Resistance to Bortezomib in Human RPMI-8226 Multiple Myeloma Cells: Molecular Characterization, Cross-Resistance with Other Proteasome Inhibitors but Marked Sensitization to Glucocorticoids

Acquisition of Mutations in the PSMB5 Gene during Chronic Exposure of Human Acute Lymphoblastic Leukemia CCRF-CEM Cells to the Proteasome Inhibitor Bortezomib

Molecular basis of bortezomib resistance: proteasome subunit β5 ( PSMB5 ) gene mutation and overexpression of PSMB5 protein

A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration

A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function

Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.

Ex Vivo Activity of Bortezomib and Dexamethasone Combinations Against Childhood Acute Leukemia Cells.

Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss

Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy

Disparate Mechanisms of Antifolate Resistance Provoked by Methotrexate and Its Metabolite 7-Hydroxymethotrexate in Leukemia Cells: Implications for Efficacy of Methotrexate Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only